Approval · Notice of Compliance 31191 · 2023
CELEXA: Notice of Compliance 31191
Issued July 10, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31191
- Date
- July 10, 2023
- Company
- Lundbeck Canada IncSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update the Product Monograph (PM) with safety information following an update to Lundbeck¿s Company Core Data Sheet (CCDS) for citalopram regarding hyperprolactinemia.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CELEXA | Not yet assigned | — |
Medicinal ingredients
- CITALOPRAM HYDROBROMIDE 10 MG per TAB
- CITALOPRAM HYDROBROMIDE 20 MG per TAB
- CITALOPRAM HYDROBROMIDE 40 MG per TAB